Page 17 - GTM-2-1

Global Translational Medicine Mineralocorticoid receptor in CMD

Figure 5. Role of mineralocorticoid receptor (MR) in the pathogenesis of cardiometabolic diseases. MR is expressed in a variety of cells and contributes to
the pathological processes of cardiometabolic diseases. ECM: Extracellular matrix; SMC: Smooth muscle cell.

conditions such as hypertension, MI, and atherosclerosis, tissue has also not been fully explored. Elucidating the role
require further investigations. of MR in these tissues will help to paint a more complete
picture of the function of MR and will likely provide a more
8. Conclusions and perspectives comprehensive basis for new therapeutic strategies.

MR has been studied for more than 30 years, and MRAs, including steroidal and non-steroidal classes,
substantial progress has been made in the understanding are commonly used to treat CVDs in clinical practice. The
of the role of MR in CMDs. MR is expressed in almost all novel non-steroidal MRA, finerenone, has a lower risk of
tissues and organs involved in cardiovascular homeostasis hyperkalemia than steroidal MRAs due to differences in
and participates in the pathophysiological process of tissue distribution, receptor inactivation, drug half-life, and
CMDs (Figure 5). Inhibiting the functional activity other factors. Recently, an increasing number of evidence
of MR in these tissues may improve CMD outcomes. has shown that finerenone could significantly improve renal
Although many animal experiments and clinical trials have prognosis and reduce the risk of CVD in adult patients with
described the function and role of MR in different tissues chronic kidney disease and T2DM. However, it still lacks
as comprehensively as possible, MR will continue to be an direct evidence to support the application of finerenone
interesting and important research topic in CMDs, as many in the treatment of CVDs, such as HF, MI, atherosclerosis,
questions remain to be answered. The role of MR in some and hypertension. Illuminating the beneficial effects (and
important tissues and cells has not been fully elucidated. For possibly side effects) of finerenone in CMDs will facilitate
example, it is still not known whether B-cell MR plays a key a broader application of this drug in clinical practice and
role in the pathology of CMDs. The role of MR in adipose inspire the development of the next generations of MRAs.

Volume 2 Issue 1 (2023) 11 https://doi.org/10.36922/gtm.v2i1.229